Bimzelx 320 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F6U9W
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,358
Award facts
- Contract value 100% obligated
- $10,357.97 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,357.97 to AmerisourceBergen Drug Corp for the supply of BIMZELX 320 mg/2 mL auto-injector units. The contract, issued on December 16, 2025, with an ultimate completion date of December 17, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle that extends through December 2026.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical federal vendor for military and veteran healthcare systems. The company's existing contract portfolio with DLA encompasses a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. BIMZELX is a biologic immunosuppressant used in rheumatology and dermatology applications, reflecting the breadth of specialized pharmaceutical products the company supplies to support Defense Health Agency and other federal healthcare systems. The DLA is transitioning to Pharmaceutical Prime Vendor Global Program Generation V contracts with plans for multiple regional awards, positioning AmerisourceBergen within a competitive federal medical supply ecosystem.
Quick answers
Who was awarded contract SPE2DR26F6U9W?
SPE2DR26F6U9W was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 16, 2025.
How much is contract SPE2DR26F6U9W worth?
The government has obligated $10,358 on SPE2DR26F6U9W.
Is contract SPE2DR26F6U9W an order under another contract?
Yes. SPE2DR26F6U9W is a delivery order under SPE2DR25D3013, an indefinite delivery contract.
Was contract SPE2DR26F6U9W competed?
The extent of competition for SPE2DR26F6U9W was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award